"We are leveraging our deep expertise in ACLY biology to expand our portfolio beyond NEXLETOL (bempedoic acid)/NEXLIZET (bempedoic acid and ezetimibe) and to address the urgent needs of patients living with PSC," said Sheldon Koenig, Chief Executive Officer at Esperion. "Our lead candidates, including ESP- 1336, are promising, potential first-in-class allosteric ACLY inhibitors, well-characterized with significant preclinical data, and represent a natural extension of our metabolic franchise. PSC is a rare ...